Skip to main content
SpringerLink
Log in

Renin inhibition

  • Review
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Modification of the renin-angiotensin-aldosterone system by renin inhibitors may be an alternative to angiotensin-converting enzyme inhibitors in the treatment of cardio-vascular disease. The development of clinically useful renin inhibitors has been hampered by a variety of pharmacologic problems, most notably the poor oral bioavailability of these peptide-related compounds. Peptidomimetic renin inhibitors that have been stabilized to enzymatic degradation in conjunction with optimizing physical characteristics amenable to intestinal absorption offer the greatest promise to date. Studies in animal models demonstrate that renin inhibitors are capable of reducing both systolic and diastolic blood pressures without causing reflex tachycardia. The response appears to be sustained with chronic administration. The beneficial cardiovascular effects of these compounds have been confirmed in the few studies conducted in patients with hypertension and in those with congestive heart failure. Further development of renin inhibitors is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adedoyin A, Perry PR, Wilkinson GR, et al. Hepatic elimination in the rat of ditekiren (U-71038), a renin inhibitor pseudohexapeptide.Drug Metab Dispos 1993;21:184–188.

    Google Scholar 

  • Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.N Engl J Med 1991;324:1098–1104.

    Google Scholar 

  • Andoh TF, Nagotomi I, Horiai H, et al. Comparative effects of FK 906 an orally active renin inhibitor and captopril on blood pressure and renal hemodynamics in cynomolgus monkeys.J Am Soc Nephrol 1992;3:557.

    Google Scholar 

  • Blaine EH, Shorn TW, Boger J. Statine-containing renin inhibitor: Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs.Hypertension 1984;6(Suppl I):I111-I118.

    Google Scholar 

  • Blaine EH, Nelson BJ, Seymour AA, et al. Comparison of renin and converting enzyme inhibition in sodium-deficient dogs.Hypertension 1985;7(Suppl I):I66-I71.

    Google Scholar 

  • Boger RS, Glassman HN, Cavanaugh JH, et al. Prolonged duration of blood pressure response to the novel, dipeptide renin inhibitor, enalkiren, in essential hypertension.Hypertension 1990;15:835–840.

    Google Scholar 

  • Boger RS, Glassman HN, Thys R, Gupta RL, Hippensteel R, Kleinert HD. Absorption and blood pressure response to the new orally active renin inhibitor, A-72517, in hypertensive patients.Am J Hypertens 1993;6:103A.

    Google Scholar 

  • Bolis G, Fung AKL, Greer J, et al. Renin inhibitors: Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond.J Med Chem 1987;30:1729–1737.

    Google Scholar 

  • Burton J, Cody RJ, Herd JA, et al. Specific inhibition of renin by an angiotensinogen analog: Studies in sodium depletion and renin-dependent hypertension.Proc Natl Acad Sci 1980;77:5476–5479.

    Google Scholar 

  • Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II receptor subtypes.Biochem Biophys Res Commun 1989;165:196–203.

    Google Scholar 

  • Cordero P, Fisher ND, Moore TJ, et al. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans.Hypertension 1991;17:510–516.

    Google Scholar 

  • Dayton BD, Stein HH, Cohen J, et al. Effects of angiotensinase inhibitors on plasma protein binding and IC50 determinations of renin inhibitors.Clin Chem 1992;38:2239–2243.

    Google Scholar 

  • deClaviere M, Fourment P, Richaud JP, et al. Hemodynamic effects of the renin inhibitor SR 42128 in conscious baboons.J Hypertens 1985;3(Suppl 3):S271-S273.

    Google Scholar 

  • de Gasparo M, Cumin F, Nussberger J, et al. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers.Br J Clin Pharmacol 1989;27:587–596.

    Google Scholar 

  • Derkx FHM, van den Meiracker AH, Fischli W, et al. Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects: An assayrelated artifact.Am J Hypertens 1990;4:602–609.

    Google Scholar 

  • El Amrani AIK, Menard J, Gonzales MF, et al. Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamies of normotensive guinea pigs.J Cardiovasc Pharmacol 1993;22:231–239.

    Google Scholar 

  • Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years.Hypertension 1990;16:363–370.

    Google Scholar 

  • Fischli W, Clozel JP, El Amrani K, et al. Ro 42-5892 is a potent orally active renin inhibitor in primates.Hypertension 1991;18:22–31.

    Google Scholar 

  • Fisher NDL, Allan D, Kifor I, et al. A comparison of ACE and renin inhibition in men.Am J Hypertens 1993;6:52A.

    Google Scholar 

  • Fisher NDL, Hollenberg N. Renal vascular responses to renin inhibition with zankiren in men.J Clin Pharm and Therapeutics 1995;57:342–348.

    Google Scholar 

  • Gavras H, Gavras I. Angiotensin converting enzyme inhibitors: Properties and side effects.Hypertension 1988;11(Suppl II):II37-II41.

    Google Scholar 

  • Gupta SK, Granneman R, Boger RS, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor) I: Single dose study.Drug Met Disposition 1992a;20:821–825.

    Google Scholar 

  • Gupta SK, Granneman GR, Glassman H, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) modeling of Abbott-72517 (a new renin inhibitor, RI): A relative bioavailability study.Pharm Res 1992b;9:S303.

    Google Scholar 

  • Hofbauer KG, Wood JM, Gulati N, et al. Increased plasma renin during renin inhibition: Studies with a novel immunoassay.Hypertension 1985;7(Suppl I):I61-I65.

    Google Scholar 

  • Hollenberg, NK. Strategies in antihypertensive therapy: Implications of the kidney.Am J Med 1986;81:15–19.

    Google Scholar 

  • Hsueh WA. Inactive renin in human plasma: Is it prorenin?Miner Electrolyte Metab 1982;7:169–178.

    Google Scholar 

  • Humke U, Levens N, Wood J, Hofbauer K. Responses to renin inhibition in conscious primates.Am J Physiol 1991;261:F179-F186.

    Google Scholar 

  • Ihara Y, Maruyama K, Terakawa M, Azuma J. Pharmacological investigations of oral FK906, a new renin inhibitor, in healthy volunteers.Proceedings of the 5th World Conference on Clinical Pharmacology and Therapeutics (July 26–31, 1992, Yokahama, Japan, abstr. P-301-07.

  • Iizuka K, Kamijo T, Kubota T, et al. New human renin inhibitors containing an unnatural amino acid, norstatine.J Med Chem 1988;31:701–704.

    Google Scholar 

  • Jeunemaitre X, Menard J, Nussberger J, et al. Plasma angiotensins, renin and blood pressure during acute renin inhibition by CGP 38560A in hypertensive patients.Am J Hypertens 1989;2:819–827.

    Google Scholar 

  • Keiser JA, Romero JC, Kost LJ, et al. Hepatic extraction of renin: Quantitation and characterization in the isolated perfused rat liver.Hepatology 1987;7:1254–1261.

    Google Scholar 

  • Kim S, Iwao H, Nakamura N, et al. Fate of circulating renin in conscious rats.Am J Physiol 1987;252:E136-E146.

    Google Scholar 

  • Kleinbloesem CH, Weber C, Fahrner E, et al. Hemodynamic, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects.Clin Pharmacol Ther 1993;53:585–592.

    Google Scholar 

  • Kleinert HD, Martin D, Chekal M, et al. Cardiovascular actions of the primate-selective renin inhibitor, A-62198.J Pharmacol Exp Ther 1988a;246:975–979.

    Google Scholar 

  • Kleinert HD, Martin D, Chekal M, et al. Effects of renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity.Hypertension 1988b;11:613–619.

    Google Scholar 

  • Kleinert HD, Luly JR, Bopp BA, et al. Profile of the renin inhibitor, enalkiren (Abbott-64662).Cardiovasc Drug Rev 1990;8:203–219.

    Google Scholar 

  • Kleinert HD, Baker WR, Stein HH. Renin inhibitors.Adv Pharmacol 1991;22:207–250.

    Google Scholar 

  • Kleinert HD, Rosenberg SH, Baker WR, et al. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy.Science 1992a;257:1940–1943.

    Google Scholar 

  • Kleinert HD, Stein HH, Boyd SA, et al. Discovery of a well-absorbed efficacious renin inhibitor, A-74273.Hypertension 1992b;20:768–775.

    Google Scholar 

  • Kobrin I, Viskoper RJ, Laszt A, et al. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension.Am J Hypertens 1993;6:349–356.

    Google Scholar 

  • Kokubu T, Hiwada K, Murakami E, et al. ES-8891, an orally active inhibitor of human renin.Hypertension 1990;15:909–913.

    Google Scholar 

  • Mangiapane ML, Murphy WR, Schelhorn TM, et al. Hemodynamic effects of CP-80,794, an orally active renin inhibitor (RI).FASEB J 1990;4:A748.

    Google Scholar 

  • Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease.N Engl J Med 1993;329:616–619.

    Google Scholar 

  • Morishima H, Koike Y, Nakano M, et al. A novel nonpeptidic, orally active renin inhibitor.Biochem Biophys Res Commun 1989;159:999–1005.

    Google Scholar 

  • Morris BJ. New possibilities for intracellular renin and inactive renin now that the structure of human renin gene has been elucidated.Clin Sci 1986;71:345–355.

    Google Scholar 

  • Nelson DE, Moyse DM, O'Neil JM, et al. Renin inhibitor, Abbott-72517, does not induce characteristic angiotensin converting enzyme inhibitor (ACEI) cough.Circulation 1993;88:I-361.

    Google Scholar 

  • Neuberg GW, Penn J, Kukin ML, et al. Hemodynamic effects of enalkiren, a direct inhibitor of plasma renin in patients with chronic heart failure.Clin Res 1990;38:253A.

    Google Scholar 

  • Nisato D, Lacour C, Roccon A, et al. Discovery and pharmacological characterization of highly potent, picomolar-range, renin inhibitors.J Hypertens 1987;5(Suppl 5):S23-S25.

    Google Scholar 

  • Nussberger J, Delabays A, de Gasparo M, et al. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers.Hypertension 1989;13:948–953.

    Google Scholar 

  • Ogihara T, Nagano M, Higaki J, et al. Antihypertensive efficacy of FK906, a novel human renin inhibitor.Clin Ther 1993;15:539–548.

    Google Scholar 

  • Ondetti MA, Cushman DW. Inhibition of the renin-angiotensin system: A new approach to the therapy of hypertension.J Med Chem 1981;24:355–361.

    Google Scholar 

  • Ohtawa M, Takayama F, Saitoh K, et al. Pharmacokinetic and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.Br J Clin Pharmacol 1993;35:290–297.

    Google Scholar 

  • Patt WC, Hamilton HW, Taylor MD, et al. Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.J Med Chem 1992;35:2562–2572.

    Google Scholar 

  • Pals DT, Thaisrivongs S, Lawson JA, et al. An orally active inhibitor of renin.Hypertension 1986;8:1105–1112.

    Google Scholar 

  • Pals DT, Lawson JA, Couch S. Rat model for evaluating inhibitors of human renin.J Pharmacol Methods 1990;23:239–245.

    Google Scholar 

  • Schaffer LW, Winquist RJ, Siegl PKS. Hypotensive effect of inhibition of renin and converting enzyme in normotensive African green monkeys.FASEB J 1988;2:A605.

    Google Scholar 

  • Shibasaki M, Asano M, Fukunaga Y, et al. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.Am J Hypertens 1991;4:932–938.

    Google Scholar 

  • Skeggs LT, Lentz KE, Kahn JR, et al. Kinetics of the reaction of renin with nine synthetic peptide substrates.J Exp Med 1968;128:13–34.

    Google Scholar 

  • Slater E, Merrill D, Guess H, et al. Clinical profile of angioedema associated with angiotensin converting enzyme inhibition.JAMA 1988;260:967–970.

    Google Scholar 

  • Slater EE, Strout HV, Jr. Pure human renin: Identification and characterization of two major molecular weight forms.J Biol Chem 1981;256:8164–8171.

    Google Scholar 

  • Sturani A, Chiarini C, Degli EE, et al. Heart rate control in hypertensive patients treated by captopril.Br J Clin Pharmacol 1982;14:849–855.

    Google Scholar 

  • Sweet CS, Ludden CT, Frederick CM, et al. Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure.J Cardiovasc Pharmacol 1984;6:1067–1075.

    Google Scholar 

  • Szelke M, Leckie B, Hallett A, et al. Potent new inhibitors of human renin.Nature 1982a;299:555–557.

    Google Scholar 

  • Szelke M, Leckie BJ, Tree M, et al. H-77: A potent new renin inhibitor.Hypertension 1982b;4(Suppl II):II-59–II69.

    Google Scholar 

  • Tewksbury, DA, Dart RA, Travis J. The amino terminal amino acid sequence of human angiotensinogen.Biochem Biophys Res Comm 1981;99:1311–1315.

    Google Scholar 

  • Timmermans, PBMWM, Carini DJ, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists.Am J Hypertens 1990;3:599–604.

    Google Scholar 

  • Tree M, Atrash B, Donovan B, et al. New inhibitors of human renin tested in vitro and in vivo in the anesthetized baboon.J Hypertens 1983;1:399–403.

    Google Scholar 

  • Tree M, MacArthur K, Inglis G, et al. Effects of the renin inhibitor H 77 on angiotensin II; arterial pressure and cardiac function in conscious dogs: Comparison with captopril.J Hypertens 1989;7(Suppl 2):S51-S55.

    Google Scholar 

  • van den Meiracker AH, Admiraal PJJ, Man in't Veld AJ, et al. Prolonged blood pressure reduction by orally active renin inhibitor Ro 42-5892 in essential hypertension.Br Med J 1990;301:205–210.

    Google Scholar 

  • Verburg KM, Kleinert HD, Kadam JRC, et al. Effects of chronic infusion of the renin inhibitor A-64662 in sodium-depleted monkeys.Hypertension 1989;13:262–272.

    Google Scholar 

  • Verburg KM, Kadam JRC, Young G, et al. Effect of intrarenal renin inhibition on renal hemodynamics and excretory function.Am J Physiol 1990;259:R7-R14.

    Google Scholar 

  • Weber MA, Neutel JM, Essinger I, et al. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor.Circulation 1990;81:1768–1774.

    Google Scholar 

  • Wessale JL, Calzadilla SV, Boyd SA, et al. Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs.J Cardiovasc Pharmacol 1993a;22:644–652.

    Google Scholar 

  • Wessale JL, Kleinert HD, Calzadilla SV, et al. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs.Am J Hypertens 1993b;6:514–521.

    Google Scholar 

  • Wood JM, Gulati N, Forgiarini P, et al. Effects of a specific and long-acting renin inhibitor in the marmoset.Hypertension 1985;7:797–803.

    Google Scholar 

  • Wood JM, Baum H-P, Jobber RA, et al. Sustained reduction in blood pressure during chronic administration of a renin inhibitor to normotensive marmosets.J Cardiovasc Pharmacol 1987;10:S96-S98.

    Google Scholar 

  • Wood JM, Criscione L, deGasparo M, et al. CGP 38 560: Orally active, low-molecular-weight renin inhibitor with high potency and specificity.J Cardiovasc Pharmacol 1989a;14:221–226.

    Google Scholar 

  • Wood JM, Jobber RA, Baum H-P, et al. Biochemical effects of prolonged renin inhibition in marmosets.J Hypertens 1989b;7:615–618.

    Google Scholar 

  • Yokosawa H, Holladay LA, Inagami T, et al. Human renal renin: Complete purification and characterization.J Biol Chem 1980;255:3498–3502.

    Google Scholar 

  • Zusman RM, Burton J, Christensen D, et al. Hemodynamic effects of a competitive renin inhibitory peptide in humans: Evidence for multiple mechanisms of action.Trans Assoc Am Physicians 1983;96:365–374.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department 48G, Abbott Laboratories, Building AP6A, 100 Abbott Park Road, 60064, Abbott Park, IL, USA

    Hollis D. Kleinert

Authors
  1. Hollis D. Kleinert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kleinert, H.D. Renin inhibition. Cardiovasc Drug Ther 9, 645–655 (1995). https://doi.org/10.1007/BF00878547

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00878547

Key Words

Search

Navigation